Idecabtagene Vicleucel Myeloma Trials

bb2121 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize myeloma tumor cells more easily.

SparkCures ID	236
Developed By	bluebird bio
Brand Name	Abecma^®
Generic Name	Idecabtagene Vicleucel
Additional Names	bb2121, ide-cel
Treatment Classifications	Adoptive Cellular Therapy CAR T Cell
Treatment Targets	B-Cell Maturation Antigen (BCMA)

All Clinical Trials

View all active clinical trials around the US.

Verified

A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant

CAR T POST HEMATOPOIETIC CELL TRANSPLANT

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Comm...

EAP FOR IDECABTAGENE VICLEUCEL

View Trial

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified

A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant

CAR T POST HEMATOPOIETIC CELL TRANSPLANT

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma

No active clinical trials

Monoclonal Gammopathy of Undetermined Significance (MGUS)

No active clinical trials

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 05, 2020

The objective response rate (ORR) in the entire treated patient population (N = 62) was 75.8% with a rate of complete response (CR) or greater of 38.7%. All 15 patients who achieved a CR or greater and had bone marrow evaluable for minimal residual disease (MRD) demonstrated MRD negativity by next-generation sequencing.

...

The most common any-grade and grade 3/4 adverse effects observed were cytopenias. Neutropenia of any grade occurred in 91.9% of patients, anemia in 75.8%, thrombocytopenia in 74.2%, leukopenia in 64.5%, and lymphopenia in 37.1%. Corresponding rates of grade 3/4 cytopenias were 88.7%, 56.5%, 56.5%, 61.3%, and 35.5%, respectively. In patients without blood count recovery within 1 month, median recovery times for neutropenia and thrombocytopenia were 1.9 months and 2.2 months, respectively.

Idecabtagene Vicleucel

ABECMA^®

Overview

Clinical Trials

A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Comm...

A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant

Published Results

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

Resources

CAR T cell therapy treatment center locator

FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma

FDA flags early deaths in CAR-T myeloma trials for J&J and Legend’s Carvykti, Bristol Myers’ Abecma

FDA/EMA Accept Ide-Cel Applications for Earlier R/R Multiple Myeloma Use

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Ide-cel Produces PFS Benefit Vs Standard Regimens in Relapsed/Refractory Multiple Myeloma

Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma

Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Conti...

CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study

Dr. Berdeja Discusses Next Steps with bb2121 in Multiple Myeloma

Idecabtagene Vicleucel

ABECMA®

Overview

Clinical Trials

Published Results

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

Resources

ABECMA^®